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Aims Randomized controlled trials have shown that cardiac resynchronization therapy (CRT) prolongs survival in
patients with heart failure. No studies have explored survival after CRT in relation to individuals in the general pop-
ulation (relative survival, RS). We sought to determine observed and RS after CRT in a nationwide cohort under-
going CRT.
...................................................................................................................................................................................................
Methods
and results
A national administrative database was used to quantify observed mortality for patients undergoing CRT. Relative
survival (RS) was quantified using life tables. In 50 084 patients [age 72.1 ± 11.6 years (mean ± standard deviation)]
undergoing CRT with (CRT-D) (n= 25 273) or without (CRT-P) defibrillation (n= 24 811) over 8.8 years (median
follow-up 2.7 years, interquartile range 1.3–4.8), expected survival decreased with age. Device type, male sex,
ischaemic heart disease, diabetes, and chronic kidney disease predicted excess mortality. In multivariate analyses,
excess mortality (analogue of RS) was lower after CRT-D than after CRT-P in all patients [adjusted hazard ratio
(aHR) 0.80, 95% confidence interval (CI) 0.76–0.84] as well as in subgroups with (aHR 0.79, 95% CI 0.74–0.84) or
without (aHR 0.82, 95% CI 0.74–0.91) ischaemic heart disease. A Charlson Comorbidity Index (CCI) >_3 portended
a higher excess mortality (aHR 3.04, 95% CI 2.76–3.34). Relative survival was higher in 2015–2017 than in 2009–
2011 (aHR 0.64, 95% CI 0.59–0.69).
...................................................................................................................................................................................................
Conclusion Reference RS data after CRT is presented. Sex, ischaemic heart disease, diabetes, chronic kidney disease, and CCI
were major determinants of RS after CRT. CRT-D was associated with a higher RS than CRT-P in patients with or
without ischaemic heart disease. Relative survival after CRT improved from 2009 to 2017.
                                                                                                                                                                                                                   
Keywords Cardiac resynchronization therapy • Implantable cardioverter-defibrillator • Mortality • Relative survival
Introduction
Randomized controlled trials (RCTs) have shown that cardiac
resynchronization therapy (CRT) prolongs survival and reduces mor-
bidity in selected patients with heart failure (HF), impaired left ven-
tricular (LV) function and a wide QRS complex. On this basis, CRT is
now accepted as a standard treatment for HF.1
In RCTs, treatment effect is usually expressed in terms of relative
or absolute risk reduction in adverse clinical outcomes in relation to
a control group. Whilst these measures are useful for quantifying
treatment effect, they perhaps lack meaning to a patient who wishes
to know how long he or she will live after undergoing CRT, com-
pared with an individual in the general population. To address this,
we can consider relative survival (RS), which is defined as the ob-
served survival divided by expected survival in the general population.
The concept of RS is well developed in the field of cancer and is in-
creasingly being used in cardiovascular disease.
Whilst RCTs are the cornerstone of modern medicine, there is an
increasing recognition of the role of real world data in healthcare
decision-making. The Food and Drug Administration (FDA),
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reinforced by the 2016 21st Century Cures Act, promotes the use of
such data to make regulatory decisions. Whilst it considers RCTs as
central in ‘establishing a baseline for device performance’, it also rec-
ognizes that RCTs generally have a narrow scope and that real world
data can provide useful information on a wider patient population in
the context of real-world clinical practice. In this study, we have ex-
plored RS after CRT in the total population of England over a period
of 9 years.
Methods
Data sources
This is a non-randomized, retrospective study exploring total mortal-
ity after a first CRT device implantation. We have used the National
Health Service Hospital Episode Statistics (HES), a data warehouse
containing data on admissions to all public hospitals in England, made
available by National Health Service Digital. Data from Wales and
Scotland is not available in HES. Mortality data was cross-validated
with the Office of National Statistics (ONS). These datasets are avail-
able to University Hospital Birmingham under a data sharing agree-
ment (section 251 of the National Health Service Act 2006), which
obviates the need for Ethical Committee approval. The study was ap-
proved by the Clinical Audit Department at the Queen Elizabeth
Hospital and conforms to the Declaration of Helsinki.
Our sample included patients who had their first CRT device im-
plantation in England between January 2009 and September 2017.
This period was chosen because coding of CRT through the National
Tariff was reliable since 2009, when coding procedures were stan-
dardized following implementation of the ‘Payment by Results’ initia-
tive. Patients who had received a conventional pacemaker or an
implantable cardioverter-defibrillator (ICD) without CRT were ex-
cluded. Records of patients undergoing both CRT-D and CRT-P
were also excluded, as shown in Figure 1. All patients were censored
on 1 October 2017. We used the earliest record of a CRT-P or
CRT-D implantation for patients with multiple admissions.
The 2007 National Institute for Clinical and Care Excellence guide-
lines recommended CRT-P for patients with non-ischaemic cardio-
myopathy (NICM). It was not until 2014 that a guideline change
recommended CRT-D for patients with NICM.2 Consequently,
England has a comparatively higher CRT-P implantation rate than the
rest of Europe and the US. This has allowed us to compare outcomes
after CRT-D and CRT-P.
Endpoints
The primary endpoint was total mortality. Survival time based on ob-
served mortality was defined as the duration between the date of im-
plant and date of death, or date of censoring. Expected survival and
mortality rates were derived from national life tables in England,
matched by age, sex, and calendar year, obtained from the Office of
National Statistics.
The secondary endpoint was expected survival, which was calcu-
lated according to abridged life tables for national life expectancy
based on 5-year age groups. Life expectancy at a given age is the aver-
age number of years a person would live, if the patient experienced
age-specific mortality rates for that time period throughout life
(ONS). We have followed the same template (Supplementary mate-
rial online, Appendix) to calculate expected years of life after CRT
implantation.
Comorbidities
Patients were regarded as having a history of hypertension, diabetes
mellitus, chronic kidney disease, or myocardial infarction if these diag-
noses appeared as primary or secondary diagnoses in any hospital
spell at any time before device implantation, according to coding dat-
ing back to 2006. The Charlson Comorbidity Index (CCI) was used
as a measure comorbidity, quantified at the same hospital spell as the
device implant and categorized as: no comorbidity (CCI = 0); mild
(CCI = 1); moderate, (CCI = 2); and severe (CCI >_ 3).
CRT-D and CRT-P implantations
N = 54 524
Exclusions
• Duplicate coding: N = 1028
• Implantation not under 
cardiology speciality: N = 295
• Age >99, N = 138
• Multiple records: N = 2979
Analytical cohort
N = 50 084
CRT-D: N = 25 273
CRT-P: N = 24 811
Figure 1 Study flowchart. CRT, cardiac resynchronization
therapy.
What’s new?
• Randomized controlled trials have not explored how long a
patient a patient is expected to live after undergoing cardiac
resynchronization therapy (CRT), compared with an individual
in the general population.
• We provide reference data on relative survival (RS) for
patients treated in real-world clinical practice.
• Relative survival was higher in younger patients, in women and
in patients without a history of ischaemic heart disease, diabe-
tes, or chronic kidney disease.
• CRT-D was associated with a higher RS than CRT-P in
patients with or without ischaemic heart disease.
• Comorbidity was associated with a markedly lower RS after
CRT.
• Relative survival after CRT improved from 2009 to 2017.
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Aetiology
The underlying aetiology of cardiomyopathy is not specifically coded
in HES, so we broadly categorized aetiology as ischaemic if there was
a previous coded diagnosis of angina pectoris, acute myocardial in-
farction, other acute ischaemic heart diseases, chronic ischaemic
heart disease, coronary artery bypass grafting, or percutaneous coro-
nary intervention. The codes used according to ICD10 and the Office
of Population Censuses and Surveys Classification of Interventions
and Procedures-4 (OPCS-4) are shown in the Supplementary mate-
rial online, Appendix.
Statistical analysis
Continuous variables are expressed as mean (±standard deviation)
and compared using the Student’s t-test. Categorical variables were
compared using the v2 statistic. Kaplan–Meier curves and the log-
rank test were used to assess observed cumulative survival. Cox pro-
portional hazard models were used to compare risks of observed
mortality. Proportionality hypotheses were first verified by visual ex-
amination of log (survival) graphs to ensure parallel slopes, and by ex-
amining Schoenfeld residuals. A two-sided P-value <_0.05 was
considered statistically significant. Statistical analyses were under-
taken using Stata 14 (StataCorp, TX, USA).
Relative survival
This is defined as the observed survival among CRT patients divided
by expected survival in the age-, sex-, and year-matched population
of England. Accordingly, excess mortality is the analogue of relative
survival. It is, in effect, the Kaplan–Meier survivor function over the
follow-up time, divided by the expected survival rate in the same
time period. We used flexible parametric survival models to estimate
excess mortality after CRT, associated with device type, sex, age,
comorbidities, ischaemic aetiology, and year of implantation. The
flexible parametric approach allowed the use of patient-level data
and continuous time. We also used restricted cubic spline functions
to estimate the baseline. Model fit was compared using log likelihood,
the Bayesian and Akaike information criteria, respectively. The cumu-
lative hazard scale was chosen for ease of comparison with the Cox
model.
Results
Baseline characteristics
Over a study period of 8.8 years, a total of 50 084 patients underwent
CRT implantation [CRT-D: 25 273 (50.5%), CRT-P: 24 811 (49.5%)]
in 173 public hospitals in England (Figure 1 and Supplementary mate-
rial online, Appendix). The nationwide numbers and distribution of
implantations increased over time, as did the proportion of CRT-D
implants, which exceeded CRT-P implants by 2014 (Figure 2).
Because of the high numbers involved, statistically significant differen-
ces (P< 0.001) were observed with respect to all baseline character-
istics, despite differences being numerically small (Table 1).
Compared with CRT-P patients, CRT-D patients were more likely to
have a history of ischaemic heart disease (67.2% vs. 56.0%), and less
likely to have hypertension (57.6% vs. 58.8%) or chronic kidney dis-
ease (12.4% vs. 15.8%) (all P< 0.001).
Observed mortality after CRT-D vs.
CRT-P
Over a median follow-up of 2.7 years (interquartile range 1.3–
4.8 years), 14 108 (28.1%) patients died, 5975 (23.6%, 8.2 per 100
person-years) after CRT-D, and 8133 (32.8%, 11.1 per 100 person-
years) after CRT-P. In Kaplan–Meier survival analyses, CRT-D was as-
sociated with a lower observed mortality than CRT-P (log rank
P< 0.001) (Supplementary material online, Appendix). All covariates
that predicted observed mortality in univariate analyses
(Supplementary material online, Appendix) were entered in multivari-
ate models. In the latter, observed mortality was lower after CRT-D
[adjusted hazard ratio (aHR) 0.85, 95% confidence interval (CI) 0.82–
0.88], after adjustment for age, sex, history of comorbidities, CCI, his-
tory of ischaemic heart disease, and year of implantation (Table 2).
Relative survival and excess mortality
When adjusting for survival in a matched population, observed sur-
vival was lower than survival in the reference population. In multivari-
able analyses, significant effects on excess mortality were observed
for most baseline variables, except for a history of hypertension
(Table 2). Excess mortality was lower in CRT-D than after CRT-P
(aHR 0.80, 95% CI 0.76–0.84).
Age
CRT-P patients were older than CRT-D patients (74.3 ± 11.3 vs.
68.1 ± 11.1 years). In univariate analyses (Supplementary material on-
line, Appendix), observed mortality increased with increasing age
[>_80 years hazard ratio (HR) 4.37, 95% CI 4.07–4.68, compared with
<60 years]. In multivariate analyses, age predicted both observed
(HR 1.04, 95% CI 1.03–1.04) and excess (HR 1.01, 95% CI 1.01–1.01)
mortality (Table 2). As shown in Table 3, the gap between expected
survival after CRT and life expectancy in the general population gen-
erally decreased with age. In the case of women >_80 years undergo-
ing CRT-D in 2015–2017 (n= 256), however, expected survival was
higher than life expectancy in the general population (Table 3,
Figure 3).
Sex
Most patients were men [37 511 (74.9%), P< 0.001] (Table 1). In uni-
variate analyses, observed mortality was higher in men (HR 1.41, 95%
CI 1.36–1.47) (Supplementary material online, Appendix). In multivari-
ate analyses, both observed (HR 0.73, 95% CI 0.70–0.76) and excess
mortality (HR 0.75, 95% CI 0.70–0.80) were lower in women than in
men. A shown in Figure 3 and Table 3, expected survival after either
CRT-D or CRT-P was consistently higher in women. Importantly,
however, survival of women in the general population was also higher
(Table 3, Figure 3).
Comorbidity
Differences in the CCI between the CRT-D and CRT-P groups were
statistically significant, albeit numerically small (Table 1). Observed
mortality increased with higher commodity (Table 3 and
Supplementary material online, Appendix). For patients with a CCI
>_3, the risk of excess mortality was 3 times higher than those with a
CCI = 0 (Table 2). As shown in Figure 3B, CCI had a profound influ-
ence on expected survival after CRT.
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Aetiology
Most patients had ischaemic heart disease [30 872 (61.6%)] (Table 1).
In univariate analyses, an ischaemic aetiology was associated with a
higher observed mortality (HR 1.44, 95% CI 1.39–1.49)
(Supplementary material online, Appendix). In multivariate analyses,
an ischaemic aetiology was associated with a higher observed (HR
1.08, 95% CI 1.04–1.13) and excess (HR 1.14, 95% CI 1.07–1.22)
mortality (Table 2).
In patients with ischaemic heart disease, CRT-D was associated
with a lower observed (aHR 0.83, 95% CI 0.80–0.87) and excess
(aHR 0.79, 95% CI 0.74–0.84) mortality than CRT-P after covariate
adjustment. In patients without a history of ischaemic heart disease,
CRT-D was also associated with a lower observed (aHR 0.88, 95%
CI 0.83–0.94) and excess (aHR 0.82, 95% CI 0.74–0.91) mortality af-
ter covariate adjustment.
Year of implantation
Compared with 2009–2011, excess mortality was lower in the pe-
riod 2012–2014 (HR 0.77, 95% CI 0.73–0.82) and in 2015–2017 (HR
0.64, 95% CI 0.59–0.69) (Table 2). The gap in expected survival for
CRT patients and survival in the general population narrowed over
the time period from 2009 to 2017 (Table 2 and Supplementary ma-
terial online, Appendix).
Other variables
The influence of other variables on observed and excess mortality af-
ter CRT-D and CRT-P is shown in Figure 4.
Discussion
This is the largest study on long-term outcomes of CRT of a real-
world, nationwide population of patients undergoing CRT, in terms
of patient numbers and length of follow-up. It has emerged in the
context of the CRT survey II which, whilst comprehensively describ-
ing CRT implantation practice in Europe, does not provide follow-up
data.3 An unique aspect of this study is the quantification of RS, which
expresses how long a patient is expected to live after CRT compared
with a matched individual in the general population. Several findings
have emerged. First, survival after CRT was lower than in the general
population at most ages. Second, RS after CRT was highest in youn-
ger patients. Third, male sex, history of ischaemic heart disease, dia-
betes, and chronic kidney disease were associated with a lower RS.
Fourth, CRT-D was associated with a higher RS than CRT-P in the
overall study sample, as well as in subgroups with or without ischae-
mic heart disease. Fifth, RS decreased with increasing comorbidities,
assessed using the CCI. Sixth, RS after CRT decreased from 2009 to
2017.
Figure 2 Implant rates in England. (A) The distribution of CRT implantations in England, in the period 2009–2017 is shown. Size and colour of
circles are proportional to implant rates. (B) The number of CRT implantations over the study period is shown. Results are presented as number of
implants per year. The year 2017 is not shown as data only extends to September. CRT, cardiac resynchronization therapy.
4 F. Leyva et al.
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Expected survival after CRT
Data on how long a CRT patient is expected to live has previously
been based on modelling analyses from RCT data.4 Arguably, how-
ever, these data do not reflect the ‘real world’, insofar as they reflect
a highly selected population with limited follow-up. In this study, we
provide empirical data from real-world clinical practice to inform on
how long a patient survives after CRT. For example, a male patient
aged 40 years lived 18.7 years after CRT-D, which compares with
40.0 years for an individual of the same age in the general population.
On the other hand, a male patient aged 85 years lived 4.3 years after
CRT-D, which compares with 5.3 years for an individual of the same
age in the general population.
Our findings indicate that, even if the treatment effect of CRT was
similar at all ages, the ‘background’ mortality governs how long a pa-
tient will survive after CRT. In other words, CRT could be equally ef-
fective at all ages, but absolute survival is also influenced by sex and
the ageing process. In this context, we should consider that RS is not
a measure of treatment effect.
CRT-D vs. CRT-P
In the Comparison of Medical Therapy, Pacing and Defibrillation in
Heart Failure (COMPANION) study, which included patients under-
going CRT-D, CRT-P or optimum medical therapy only, showed that
CRT-D was associated with a lower mortality than optimum medical
therapy. The study, however, was not designed to compare CRT-D
with CRT-P. In the DANISH (Defibrillator Implantation in Patients
with Nonischaemic Systolic Heart Failure) study, 1116 patients with
NICM were randomized to ICDs or usual care, which included CRT-
P.5 After a median follow-up period of 5.63 years, ICD did not reduce
total mortality (HR 0.87, 95% CI 0.68–1.12; P= 0.28), despite a signifi-
cant reduction in sudden cardiac death (HR 0.50, 95% CI 0.31–0.82;
P= 0.005). Notwithstanding, several meta-analyses involving higher
patient numbers have shown a benefit in total mortality from ICDs in
patients with NICM.6 In an observational study of 1500 patients, we
found that CRT-D was associated with a lower total mortality (HR
0.62) in patients with ischaemic cardiomyopathy (ICM) after propen-
sity matching.7 In contrast, total mortality after CRT-D and CRT-P
was similar in patients with NICM. Kutyifa et al.8 also showed no mor-
tality benefit from CRT-D vs. CRT-P patients with NICM. In a recent
multicentre, European cohort study of 5307 patients, Barra et al.9
found a superiority of CRT-D vs. CRT-P after propensity matching in
ICM, but not in NICM. In the present study, which involves much
higher patient numbers, we found a lower observed and excess mor-
tality after CRT-D than after CRT-P in patients with or without
ischaemic heart disease after covariate adjustment. In fact, CRT-D
.................................................................................................
Table 1 Baseline characteristics
CRT-D CRT-P All
N (50 084) 25 273 24 811 50 084
Sex (male) 20 423 (80.81) 17 088 (68.87) 37 511 (74.90)
Age (years) 68.1 ± 11.1 74.3 ± 11.3 71.2 ± 11.6
<60 4950 (19.59) 2336 (9.42) 7286 (14.55)
60–69 7184 (28.43) 4202 (16.94) 11 386 (22.73)
70–79 10 079 (39.88) 9150 (36.88) 19 229 (38.39)
>_80 3060 (12.11) 9123 (36.77) 12 183 (24.33)
Charlson Comorbidity Index
0 5924 (23.44) 7022 (28.30) 12 946 (25.85)
1 8270 (32.72) 7549 (30.43) 15 819 (31.58)
2 5765 (22.81) 4824 (19.44) 10 589 (21.14)
>_3 5314 (21.03) 5416 (21.83) 10 730 (21.42)
Ischaemic aetiology,
n (%)
16 971 (67.15) 13 901 (56.03) 30 872 (61.64)
History, n (%)
Hypertension 14 565 (57.63) 14 599 (58.84) 29 164 (58.23)
Diabetes 6905 (27.32) 6056 (24.41) 12 961 (25.88)
Chronic kidney
disease
3127 (12.37) 3924 (15.82) 7051 (14.08)
Myocardial
infarction
4092 (16.19) 2466 (9.94) 6558 (13.09)
CABG 1354 (5.36) 834 (3.36) 2188 (4.37)
All comparisons between CRT-D and CRT-P were significant (P< 0.001).
CABG, coronary artery bypass grafting; CRT, cardiac resynchronization therapy.
.................................................................................................
Table 2 Multivariable analyses
Observed
mortality
HR (95% CI)
Excess
mortality
EHR (95% CI)
CRT-D 0.85 (0.82–0.88) 0.80 (0.76–0.84)
Sex (female) 0.73 (0.70–0.76) 0.75 (0.70–0.80)
Age 1.04 (1.03–1.04) 1.01 (1.01–1.01)
<60 –
60–69 1.52 (1.41–1.64) 1.24 (1.13–1.35)
70–79 2.18 (2.04–2.34) 1.37 (1.26–1.49)
>_80 3.44 (3.20–3.70) 1.38 (1.25–1.53)
Charlson Comorbidity Index
0 –
1 1.21 (1.15–1.27) 1.44 (1.31–1.59)
2 1.50 (1.43–1.59) 2.06 (1.87–2.26)
>_3 1.95 (1.84–2.05) 3.04 (2.76–3.34)
Ischaemic aetiology 1.08 (1.04–1.13) 1.14 (1.07–1.22)
History
Hypertension 1.01 (0.97–1.04) 0.99 (0.94–1.05)
Diabetes 1.14 (1.09–1.19) 1.20 (1.13–1.27)
Chronic kidney disease 1.67 (1.59–1.75) 2.09 (1.96–2.23)
Myocardial infarction 1.17 (1.12–1.23) 1.27 (1.18–1.36)
CABG 0.74 (0.67–0.81) 0.66 (0.57–0.77)
Implant year
2009–2011 –
2012–2014 0.83 (0.80–0.87) 0.77 (0.73–0.82)
2015–2017 0.71 (0.67–0.75) 0.64 (0.59–0.69)
Analyses refer to observed mortality and excess mortality. Results are expressed
as aHR and 95% CIs.
aHR, adjusted hazard ratio; CABG, coronary artery bypass grafting; CI, confi-
dence interval; CRT, cardiac resynchronization therapy; EHR, excess hazard ra-
tios; HR, hazard ratio.
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was superior to CRT-P in most subgroup analyses. Together, these
findings suggest that only numbers as high as those presented herein
are needed to show a superiority of CRT-D over CRT-P.
Sex
Sex-specific differences in survival were not observed in
COMPANION (Comparison of Medical Therapy, Pacing and
Defibrillation in Heart Failure)10 or CARE-HF (Cardiac
Resynchronization in Heart Failure).11 However, a substudy of
MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial
with Cardiac Resynchronization Therapy) showed that survival from
CRT-D vs ICD was better in women (25% of the study population).12
These findings are also consistent with data from the US National
Cardiovascular Data Registry, in which benefit from CRT-D over
ICD was greater in women than in men with a left bundle branch
block.13 In a meta-analysis of 33 434 patients from 72 studies, women
had approximately a 33% lower total mortality HF hospitalization af-
ter CRT.14 Better outcomes in women have also been reported by
other observational studies.15,16 We found that CRT was associated
with a higher RS in women. However, survival of women in the gen-
eral population was also higher. This suggests that CRT may not nec-
essarily be more effective in women, but that women may live longer
after CRT simply because they are women. Differences in mortality
between men and women in observational CRT studies may there-
fore reflect a difference in sex-specific ‘background’ survival rather
than a difference in the effectiveness of CRT.
..................................................................................... .....................................................................................
....................................................................................................................................................................................................................
Table 3 Expected survival after CRT
Women Men
General population CRT-P CRT-D General population CRT-P CRT-D
2015–2017
40–44 43.07 22.40 22.20 39.95 19.58 18.71
45–49 38.31 17.40 19.37 35.30 14.58 16.32
50–54 33.63 15.01 17.10 30.77 11.73 15.50
55–59 29.07 13.88 16.33 26.35 9.08 12.58
60–64 24.68 12.56 13.88 22.17 8.58 10.31
65–69 20.43 9.77 13.08 18.20 7.80 9.19
70–74 16.43 8.81 11.07 14.49 6.35 7.98
75–79 12.74 8.22 9.98 11.18 6.11 6.23
80–84 9.47 6.69 10.50 8.35 5.33 5.33
85þ 5.91 5.76 11.20 5.31 4.46 4.31
2012–2014
40–44 43.00 11.05 9.83 39.76 5.94 8.90
45–49 38.24 11.29 9.89 35.12 7.20 9.23
50–54 33.57 10.22 9.13 30.57 6.82 8.00
55–59 29.01 9.59 8.25 26.15 5.70 6.69
60–64 24.62 7.64 7.57 21.97 5.82 5.54
65–69 20.39 5.84 6.18 18.03 4.06 4.81
70–74 16.39 5.07 5.06 14.37 3.69 4.38
75–79 12.72 4.53 4.13 11.09 3.24 3.61
80–84 8.51 3.59 2.79 8.30 2.52 2.75
85þ 5.01 2.98 2.21 5.33 2.10 2.58
2009–2011
40–44 42.69 14.10 9.09 39.26 4.98 10.45
45–49 37.95 9.10 9.74 34.63 4.74 7.36
50–54 33.29 7.06 7.76 30.09 5.61 6.72
55–59 28.77 6.74 7.27 25.73 5.39 6.98
60–64 24.39 8.11 5.32 21.58 4.48 6.08
65–69 20.19 5.65 5.27 17.68 3.91 4.38
70–74 16.24 4.68 4.75 14.09 3.28 3.86
75–79 12.62 3.90 3.79 10.91 2.83 3.32
80–84 8.49 3.29 3.30 8.19 2.54 2.87
85þ 5.13 2.25 4.33 5.01 2 2.47
Data refers to expected survival in years after CRT-P and CRT-D and life expectancy in the general population in England, from 2015 to 2017, from 2012 to 2014, and from
2009 to 2011.
CRT, cardiac resynchronization therapy.
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Comorbidity
Heart failure often associated with multiple comorbidities. The find-
ing that co-morbidity did not alter the survival benefit of CRT-D over
ICD in MADIT-CRT,17 is not unexpected, as RCTs tend to include
highly selected patients. In contrast, several observational studies
have shown that diabetes, renal failure, and chronic obstructive pul-
monary disease have a negative impact on survival after cardiac elec-
tronic device implantation. In an observational study of 463 CRT-D
patients, Theuns et al.18 showed that 81% of patients had at least
three comorbid conditions and that an age-adjusted CCI >_ 5 pre-
dicted mortality (HR 3.69, P< 0.001). Similarly, in a study of 697 CRT
patients, Ioannou et al.19 found that each tertile of Charlson age
comorbidity index was independently associated with a 37% higher
total mortality. We too have found that CCI as well as diabetes and
chronic kidney disease have a major impact on mortality after CRT.
Compared with a CCI = 0, a CCI >_ 3 was associated with three-fold
higher excess mortality, independent of known confounders. These
findings emphasize the importance of assessing comorbidity in risk
stratification of patients undergoing CRT.
Date of implantation
Compared with the period 2009–2011, total mortality after CRT
was 17% was lower in the period 2012–2014 and 29% lower in the
period 2015–2017. Whilst the reasons for this cannot be ascertained
by this study, this trend is not unexpected, given the increasing ten-
dency to treat patients with mild HF. Advances in drug therapy, HF
management, device optimization algorithms, and the increasing use
of quadripolar leads20 may also contribute.
Limitations
This study has the typical limitations of an observational, retrospec-
tive study using data from administrative databases which, although
rich in numbers, typically lack granularity. First, we do not have data
on New York Heart Association (NYHA) class, the aetiology of the
underlying cardiomyopathy, LV function, QRS duration or morphol-
ogy, nor medication, all of which have been linked to response after
CRT. Second, we have not included a control group on optimal medi-
cal therapy, and therefore, we cannot comment on the relative
MENA B
50
40
30
Ex
pe
ct
ed
 s
ur
vi
va
l (y
e
a
rs
)
20
10
0
40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+ 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+
40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+40-44 45-49 50-54 55-59 60-64
Age (Years)
General population
CRT-D
CRT-P
General population
CRT, CCI = 0
CRT, CCI≥ 3
Age (Years)
65-69 70-74 75-79 80-84 85+
50
40
30
Ex
pe
ct
ed
 s
ur
vi
va
l (y
e
a
rs
)
20
10
0
50
WOMEN WOMEN
40
30
Ex
pe
ct
ed
 s
ur
vi
va
l (y
e
a
rs
)
20
10
0
50
40
30
Ex
pe
ct
ed
 s
ur
vi
va
l (y
e
a
rs
)
20
10
0
MEN
Figure 3 Expected survival after CRT compared with the general population. (A) Expected survival after CRT-D (solid green) or CRT-P (solid
blue line) relative to the life expectancy in the general population in England (solid blue line), for the period 2015–2017 is shown. (B) The effect of co-
morbidity, defined in terms of the CCI is shown. For detailed calculations, see Supplementary material online, Appendix. CRT, cardiac resynchroniza-
tion therapy.
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benefits of CRT vs. medical therapy. Third, in order to explore the
relative benefits of CRT-D over CRT-P, we used history of coronary
events leading to a hospitalization as a surrogate. This, however, does
not equate to an underlying ischaemic aetiology, as patients who had
never been hospitalized may also have ischaemic heart disease.
Although a possible bias emerges from the fact that life tables also in-
clude CRT patients, this is likely to be negligible.
Conclusions
This study of a nationwide, real-world population of patients under-
going CRT provides reference data on RS after CRT, delivered in
real-world clinical practice, from the perspective of a public national
health service. RS was higher in younger patients, in women and in
patients without a history of ischaemic heart disease, diabetes or
chronic kidney disease. CRT-D was associated with a higher RS than
CRT-P in patients with or without ischaemic heart disease.
Comorbidity was associated with a worse outcome.
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